1. Executive summary
2. Global Neuroendocrine Tumors Therapeutics Market Introduction
2.1. Global Neuroendocrine Tumors Therapeutics Market – Taxonomy 2.2. Global Neuroendocrine Tumors Therapeutics Market –Definitions 2.2.1. Drug Class 2.2.2. Indication 2.2.3. Distribution Channel
3.Global Neuroendocrine Tumors Therapeutics Market Dynamics 3.1. Drivers 3.2. Restraints 3.3. Opportunities/Unmet Needs of the Market 3.4. Trends 3.5. Global Neuroendocrine Tumors Therapeutics Market Dynamics – Factors Impact Analysis 3.6. Global Neuroendocrine Tumors Therapeutics Market – Regulations 3.6.1. U.S 3.6.2. Europe 3.6.3. Japan 3.6.4. China 3.7. Global Neuroendocrine Tumors Therapeutics Market – Product Innovations
4. Global Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 4.3. Market Opportunity Analysis
5. Global Neuroendocrine Tumors Therapeutics Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024 5.1. Somatostatin Analogues 5.1.1. Octreotide 5.1.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.1.3. Market Opportunity Analysis 5.1.2. Lanreotide 5.1.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.2.3. Market Opportunity Analysis 5.1.3. Pasireotide 5.1.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.3.3. Market Opportunity Analysis 5.2. Chemotherapeutics 5.2.1. Fluorouracil (5-FU) 5.2.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.1.3. Market Opportunity Analysis 5.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil) 5.2.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.2.3. Market Opportunity Analysis 5.2.3. Streptozocin 5.2.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.3.3. Market Opportunity Analysis 5.2.4. Capecitabine (Xeloda) 5.2.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.4.3. Market Opportunity Analysis 5.2.5. Dacarbazine (DTIC) 5.2.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.5.3. Market Opportunity Analysis 5.2.6. Temozolomide (Temodar) 5.2.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.6.3. Market Opportunity Analysis 5.2.7. Oxaliplatin (Eloxatin) 5.2.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.7.3. Market Opportunity Analysis 5.3. Targeted Therapeutics 5.3.1. Sunitinib 5.3.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.3.1.3. Market Opportunity Analysis 5.3.2. Everolimus 5.3.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.3.2.3. Market Opportunity Analysis 5.4. Others 5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.4.3. Market Opportunity Analysis
6. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Indication, 2013 – 2017 and Forecast, 2018 – 2024 6.1. Lung NET 6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.1.3. Market Opportunity Analysis 6.2. Gastrointestinal NET 6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.2.3. Market Opportunity Analysis 6.3. Pancreatic NET 6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.3.3. Market Opportunity Analysis 6.4. Others 6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.4.3. Market Opportunity Analysis
7. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Distribution Channel , 2013 – 2017 and Forecast, 2018 – 2024 7.1. Retail Pharmacies 7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.1.3. Market Opportunity Analysis 7.2. Hospital Pharmacies 7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.2.3. Market Opportunity Analysis 7.3. Others 7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.3.3. Market Opportunity Analysis
8. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 8.1. North America 8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.1.3. Market Opportunity Analysis 8.2. Europe 8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.2.3. Market Opportunity Analysis 8.3. Asia-Pacific 8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.3.3. Market Opportunity Analysis 8.4. Latin America 8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.4.3. Market Opportunity Analysis 8.5. Middle East and Africa 8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 8.5.3. Market Opportunity Analysis 8.6. Global Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Class, Indication, Distribution Channel and Region, 2018 – 2024
9. North America Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 9.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 9.1.1.1. Somatostatin Analogues 9.1.1.1.1. Octreotide 9.1.1.1.2. Lanreotide 9.1.1.1.3. Pasireotide 9.1.1.2. Chemotherapeutics 9.1.1.2.1. Fluorouracil (5-FU) 9.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil) 9.1.1.2.3. Streptozocin 9.1.1.2.4. Temozolomide (Temodar) 9.1.1.2.5. Capecitabine (Xeloda) 9.1.1.2.6. Dacarbazine (DTIC) 9.1.1.2.7. Oxaliplatin (Eloxatin) 9.1.1.3. Targeted Therapeutics 9.1.1.3.1. Sunitinib 9.1.1.3.2. Everolimus 9.1.1.4. Others 9.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 9.1.2.1. Lung NET 9.1.2.2. Others NET 9.1.2.3. Gastrointestinal NET 9.1.2.4. Pancreatic NET 9.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 9.1.3.1. Retail Pharmacies 9.1.3.2. Hospital Pharmacies 9.1.3.3. Others 9.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 9.1.4.1. US 9.1.4.2. Canada 9.1.5. North America Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel, and Country, 2018 – 2024 9.1.6. North America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
10. Europe Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 10.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.1.1.1. Somatostatin Analogues 10.1.1.1.1. Octreotide 10.1.1.1.2. Lanreotide 10.1.1.1.3. Pasireotide 10.1.1.2. Chemotherapeutics 10.1.1.2.1. Fluorouracil (5-FU) 10.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil) 10.1.1.2.3. Streptozocin 10.1.1.2.4. Temozolomide (Temodar) 10.1.1.2.5. Capecitabine (Xeloda) 10.1.1.2.6. Dacarbazine (DTIC) 10.1.1.2.7. Oxaliplatin (Eloxatin) 10.1.1.3. Targeted Therapeutics 10.1.1.3.1. Sunitinib 10.1.1.3.2. Everolimus 10.1.1.4. Others 10.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.1.2.1. Lung NET 10.1.2.2. Others NET 10.1.2.3. Gastrointestinal NET 10.1.2.4. Pancreatic NET 10.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.1.3.1. Retail Pharmacies 10.1.3.2. Hospital Pharmacies 10.1.3.3. Others 10.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.1.4.1. Germany 10.1.4.2. UK 10.1.4.3. France 10.1.4.4. Spain 10.1.4.5. Italy 10.1.4.6. Russia 10.1.4.7. Poland 10.1.4.8. Rest of Europe 10.1.5. Europe Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024 10.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
11. Asia-Pacific Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 11.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.1.1.1. Somatostatin Analogues 11.1.1.1.1. Octreotide 11.1.1.1.2. Lanreotide 11.1.1.1.3. Pasireotide 11.1.1.2. Chemotherapeutics 11.1.1.2.1. Fluorouracil (5-FU) 11.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil) 11.1.1.2.3. Streptozocin 11.1.1.2.4. Temozolomide (Temodar) 11.1.1.2.5. Capecitabine (Xeloda) 11.1.1.2.6. Dacarbazine (DTIC) 11.1.1.2.7. Oxaliplatin (Eloxatin) 11.1.1.3. Targeted Therapeutics 11.1.1.3.1. Sunitinib 11.1.1.3.2. Everolimus 11.1.1.4. Others 11.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.1.2.1. Lung NET 11.1.2.2. Others NET 11.1.2.3. Gastrointestinal NET 11.1.2.4. Pancreatic NET 11.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.1.3.1. Retail Pharmacies 11.1.3.2. Hospital Pharmacies 11.1.3.3. Others 11.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.1.4.1. Japan 11.1.4.2. China 11.1.4.3. India 11.1.4.4. ASEAN 11.1.4.5. Australia & New Zealand 11.1.4.6. Rest of Asia-Pacific 11.1.5. Asia-Pacific Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024 11.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
12. Latin America Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 12.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.1.1.1. Somatostatin Analogues 12.1.1.1.1. Octreotide 12.1.1.1.2. Lanreotide 12.1.1.1.3. Pasireotide 12.1.1.2. Chemotherapeutics 12.1.1.2.1. Fluorouracil (5-FU) 12.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil) 12.1.1.2.3. Streptozocin 12.1.1.2.4. Temozolomide (Temodar) 12.1.1.2.5. Capecitabine (Xeloda) 12.1.1.2.6. Dacarbazine (DTIC) 12.1.1.2.7. Oxaliplatin (Eloxatin) 12.1.1.3. Targeted Therapeutics 12.1.1.3.1. Sunitinib 12.1.1.3.2. Everolimus 12.1.1.4. Others 12.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.1.2.1. Lung NET 12.1.2.2. Others NET 12.1.2.3. Gastrointestinal NET 12.1.2.4. Pancreatic NET 12.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.1.3.1. Retail Pharmacies 12.1.3.2. Hospital Pharmacies 12.1.3.3. Others 12.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.1.4.1. Brazil 12.1.4.2. Mexico 12.1.4.3. Argentina 12.1.4.4. Venezuela 12.1.4.5. Rest of Latin America 12.1.5. Latin America Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024 12.1.6. Latin America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
13. Middle East and Africa Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 13.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.1.1.1. Somatostatin Analogues 13.1.1.1.1. Octreotide 13.1.1.1.2. Lanreotide 13.1.1.1.3. Pasireotide 13.1.1.2. Chemotherapeutics 13.1.1.2.1. Fluorouracil (5-FU) 13.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil) 13.1.1.2.3. Streptozocin 13.1.1.2.4. Temozolomide (Temodar) 13.1.1.2.5. Capecitabine (Xeloda) 13.1.1.2.6. Dacarbazine (DTIC) 13.1.1.2.7. Oxaliplatin (Eloxatin) 13.1.1.3. Targeted Therapeutics 13.1.1.3.1. Sunitinib 13.1.1.3.2. Everolimus 13.1.1.4. Others 13.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.1.2.1. Lung NET 13.1.2.2. Others NET 13.1.2.3. Gastrointestinal NET 13.1.2.4. Pancreatic NET 13.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.1.3.1. Retail Pharmacies 13.1.3.2. Hospital Pharmacies 13.1.3.3. Others 13.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.1.4.1. Gulf Cooperation Council (GCC) Countries 13.1.4.2. Israel 13.1.4.3. South Africa 13.1.4.4. Rest of MEA 13.1.5. MEA Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index by Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024 13.1.6. MEA Neuroendocrine Tumors Therapeutics Market Dynamics – Trends
14. Competition Landscape 14.1. Strategic Dashboard of Top Market Players 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis) 14.2.1. Pfizer Inc., (U.S) 14.2.2. Eli Lilly & Company (U.S.) 14.2.3. Novartis AG (Switzerland) 14.2.4. F. Hoffmann-La Roche Ltd. (Switzerland) 14.2.5. Ipsen (France) 14.2.6. Amgen, Inc. (U.S.) 14.2.7. Teva Pharmaceuticals, Ltd. (Israel) 14.2.8. Bristol-Myers Squibb (U.S.) 15. Research Methodology
16. Key Assumptions and Acronyms